TY - JOUR
T1 - PET Imaging of CD8 via SMART for Monitoring the Immunotherapy Response
AU - Sun, Lingyi
AU - Li, Zhonghan
AU - Ma, Yongyong
AU - Ludwig, Johannes
AU - Kim, Hyun S.
AU - Zeng, Dexing
N1 - Publisher Copyright:
© 2021 Lingyi Sun et al.
PY - 2021
Y1 - 2021
N2 - Imaging of CD8 receptors on T-cells by positron emission tomography (PET) has been considered a promising strategy for monitoring the treatment response to immunotherapy. In this study, a trial of imaging CD8 with our newly developed sequential multiple-agent receptor targeting (SMART) technology was conducted. Mice bearing a subcutaneous colorectal CT26 tumor received three times different immunotherapy treatments (PD1 or CTLA4 or combined). On either day 7 or day 14 after the first time treatment, the PET imaging study was performed with sequentially administered TCO-modified anti-CD8 antibody and 64Cu-labeled MeTz-NOTA-RGD. However, no positive response was detected, probably due to (1) inappropriate selection of biomarkers for the SMART strategy, (2) limited TCO modification on the anti-CD8 antibody, and (3) inadequate response of the CT26 tumor to the selected immunotherapies. Therefore, the potential of applying SMART in imaging CD8 was not demonstrated in this study, and further optimization will be necessary before it can be applied in imaging CD8.
AB - Imaging of CD8 receptors on T-cells by positron emission tomography (PET) has been considered a promising strategy for monitoring the treatment response to immunotherapy. In this study, a trial of imaging CD8 with our newly developed sequential multiple-agent receptor targeting (SMART) technology was conducted. Mice bearing a subcutaneous colorectal CT26 tumor received three times different immunotherapy treatments (PD1 or CTLA4 or combined). On either day 7 or day 14 after the first time treatment, the PET imaging study was performed with sequentially administered TCO-modified anti-CD8 antibody and 64Cu-labeled MeTz-NOTA-RGD. However, no positive response was detected, probably due to (1) inappropriate selection of biomarkers for the SMART strategy, (2) limited TCO modification on the anti-CD8 antibody, and (3) inadequate response of the CT26 tumor to the selected immunotherapies. Therefore, the potential of applying SMART in imaging CD8 was not demonstrated in this study, and further optimization will be necessary before it can be applied in imaging CD8.
UR - http://www.scopus.com/inward/record.url?scp=85108564911&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85108564911&partnerID=8YFLogxK
U2 - 10.1155/2021/6654262
DO - 10.1155/2021/6654262
M3 - Article
C2 - 34212037
AN - SCOPUS:85108564911
SN - 2314-6133
VL - 2021
JO - BioMed Research International
JF - BioMed Research International
M1 - 6654262
ER -